

Manfred P Wirth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3877198/publications.pdf>

Version: 2024-02-01

131
papers

3,796
citations

147726

31
h-index

138417

58
g-index

131
all docs

131
docs citations

131
times ranked

5537
citing authors

#	ARTICLE	IF	CITATIONS
1	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	0.9	239
2	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program. <i>Journal of Urology</i> , 2002, 168, 429-435.	0.2	206
3	BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS. <i>Journal of Urology</i> , 2004, 172, 1865-1870.	0.2	196
4	Aldehyde Dehydrogenase Is Regulated by β -Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 1482-1494.	0.4	195
5	Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. <i>European Urology</i> , 2017, 72, 424-431.	0.9	165
6	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. <i>European Urology</i> , 2014, 66, 156-163.	0.9	156
7	Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. <i>BJU International</i> , 2015, 116, 93-101.	1.3	123
8	Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. <i>Prostate</i> , 2006, 66, 811-821.	1.2	109
9	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , 2021, 80, 703-711.	0.9	108
10	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 357-368.	0.9	105
11	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 66, 191-199.	0.9	100
12	Prospective Randomized Trial Comparing Flutamide as Adjuvant Treatment versus Observation after Radical Prostatectomy for Locally Advanced, Lymph Node-Negative Prostate Cancer. <i>European Urology</i> , 2004, 45, 267-270.	0.9	99
13	Antiandrogens in the Treatment of Prostate Cancer. <i>European Urology</i> , 2007, 51, 306-314.	0.9	84
14	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 142-150.	0.9	80
15	Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. <i>Prostate</i> , 1998, 36, 85-91.	1.2	76
16	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 265-273.	2.6	75
17	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2014, 66, 628-632.	0.9	72
18	Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+T cells in prostate cancer patients. <i>International Journal of Cancer</i> , 2002, 102, 390-397.	2.3	69

#	ARTICLE	IF	CITATIONS
19	Direct comparison of multiparametric magnetic resonance imaging (<sc>MRI</sc>) results with final histopathology in patients with proven prostate cancer in <sc>MRI</sc>/ultrasonographyâ€fusion biopsy. BJU International, 2016, 118, 213-220.	1.3	68
20	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. Cancer Research, 2016, 76, 2637-2651.	0.4	62
21	Dendritic Cell-Based Immunotherapy for Prostate Cancer. Clinical and Developmental Immunology, 2010, 2010, 1-8.	3.3	60
22	Online Professionalismâ€™2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	0.9	53
23	Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate, 2003, 56, 270-279.	1.2	48
24	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	0.9	48
25	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsyâ€naïve patients. BJU International, 2018, 121, 53-60.	1.3	47
26	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	2.6	46
27	High volume is the key for improving in-hospital outcomes after radical prostatectomy: a total population analysis in Germany from 2006 to 2013. World Journal of Urology, 2017, 35, 1045-1053.	1.2	42
28	Characterization of different carbon nanotubes for the development of a mucoadhesive drug delivery system for intravesical treatment of bladder cancer. International Journal of Pharmaceutics, 2015, 479, 357-363.	2.6	41
29	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	0.9	36
30	Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. Clinical Biochemistry, 2019, 64, 60-63.	0.8	36
31	Relationship of the Number of Removed Lymph Nodes to Bladder Cancer and Competing Mortality After Radical Cystectomy. European Urology, 2014, 66, 987-990.	0.9	34
32	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
33	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362.	0.9	31
34	MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2249-2261.	1.2	30
35	Functionalization of carbon encapsulated iron nanoparticles. Journal of Nanoparticle Research, 2010, 12, 513-519.	0.8	29
36	Prediction of cancerâ€™specific survival after radical cystectomy in <sc>pT4a</sc> urothelial carcinoma of the bladder: development of a tool for clinical decisionâ€™making. BJU International, 2016, 117, 272-279.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. <i>European Urology</i> , 2016, 69, 984-987.	0.9	27
38	Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014. <i>Annals of Surgical Oncology</i> , 2018, 25, 3502-3509.	0.7	27
39	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. <i>Oncotarget</i> , 2018, 9, 27293-27304.	0.8	27
40	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
41	Lack of Ephrin Receptor A1 Is a Favorable Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e102262.	1.1	24
42	Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1171-1182.	1.2	23
43	Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 1123-1129.	1.2	21
44	Optimal treatment of locally advanced prostate cancer. <i>World Journal of Urology</i> , 2007, 25, 169-176.	1.2	20
45	In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014. <i>Urologia Internationalis</i> , 2019, 102, 284-292.	0.6	20
46	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	1.6	18
47	ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1117.	1.8	18
48	Growth of a Level III Vena Cava Tumor Thrombus Within 1 Month. <i>Urology</i> , 2016, 90, e1-e2.	0.5	16
49	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. <i>BMC Cancer</i> , 2017, 17, 790.	1.1	16
50	Penile cancer - Incidence, mortality, and survival in Saxony, Germany. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 295.e1-295.e8.	0.8	16
51	Adjuvant Hormonal Treatment - The Bicalutamide Early Prostate Cancer Program. , 2008, 41, 39-48.		15
52	Validation of an Age-adjusted Prostate Cancer-specific Comorbidity Index. <i>European Urology</i> , 2016, 69, 764-766.	0.9	15
53	PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. <i>Case Reports in Urology</i> , 2017, 2017, 1-3.	0.1	15
54	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15

#	ARTICLE	IF	CITATIONS
55	The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1122.	1.7	15
56	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3814.	1.8	15
57	ProstaTrend – A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. <i>European Urology</i> , 2020, 78, 452-459.	0.9	15
58	Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 401-414.	1.2	14
59	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1757-1769.	1.2	14
60	Quantification of MicroRNAs in Urine-Derived Specimens. <i>Methods in Molecular Biology</i> , 2018, 1655, 201-226.	0.4	13
61	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 578.	1.3	13
62	Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older. <i>European Urology</i> , 2017, 71, 710-713.	0.9	12
63	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. <i>Urologia Internationalis</i> , 2018, 100, 155-163.	0.6	12
64	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. <i>BMC Urology</i> , 2018, 18, 91.	0.6	12
65	Validation of the Preoperative Score to Predict Postoperative Mortality in Patients Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2019, 5, 197-200.	1.6	12
66	Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. <i>Urology</i> , 2017, 101, e5-e6.	0.5	11
67	Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. <i>Urologia Internationalis</i> , 2019, 102, 96-101.	0.6	11
68	Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation. <i>Beilstein Journal of Nanotechnology</i> , 2017, 8, 1307-1317.	1.5	10
69	Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria. <i>Urologia Internationalis</i> , 2021, 105, 278-284.	0.6	10
70	Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 1121-1130.	1.4	9
71	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 11.e1-11.e6.	0.8	9
72	Does increasing life expectancy affect competing mortality after radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 413-418.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. <i>Oncology Letters</i> , 2016, 12, 3143-3152.	0.8	8
74	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. <i>Urology</i> , 2016, 94, e1-e2.	0.5	8
75	Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 432.e1-432.e8.	0.8	8
76	Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. <i>World Journal of Urology</i> , 2017, 35, 245-250.	1.2	8
77	Online support groups offer low-threshold backing for family and friends of patients with prostate cancer. <i>European Journal of Cancer Care</i> , 2019, 28, e12982.	0.7	8
78	Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 645.	1.0	7
79	Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy. <i>Urologia Internationalis</i> , 2020, 104, 567-572.	0.6	7
80	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
81	\hat{I}^2 -Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in \hat{I}^2 -Adrenoceptor Knockout Mice. <i>Frontiers in Pharmacology</i> , 2016, 7, 118.	1.6	6
82	Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of \hat{I}^2 -catenin in prostate cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2201-2210.	1.2	6
83	Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. <i>Urologia Internationalis</i> , 2019, 102, 20-26.	0.6	6
84	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. <i>Urologia Internationalis</i> , 2019, 103, 427-432.	0.6	6
85	Only 10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>European Urology Focus</i> , 2019, 5, 361-364.	1.6	6
86	Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?. <i>World Journal of Urology</i> , 2020, 38, 695-702.	1.2	6
87	Androgen Deprivation Therapy and Alzheimer's Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2801-2801.	0.8	5
88	Quantifying the Relationship Between Increasing Life Expectancy and Nonprostate Cancer Mortality After Radical Prostatectomy. <i>Urology</i> , 2020, 142, 174-178.	0.5	5
89	Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCR. <i>Cancers</i> , 2021, 13, 4459.	1.7	5
90	Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20661-e20661.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	0.8	5
92	Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer. Drugs and Aging, 2003, 20, 115-124.	1.3	4
93	Mucosa of murine detrusor impairs β_2 -adrenoceptor-mediated relaxation. Neurourology and Urodynamics, 2015, 34, 592-597.	0.8	4
94	Renal Sarcoidosis Mimicking Xanthogranulomatous Pyelonephritis. Urology, 2016, 97, e19-e20.	0.5	4
95	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. Cells, 2021, 10, 1315.	1.8	4
96	Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program. Oncology, 2003, 65, 1-4.	0.9	4
97	Perspectives in Adjuvant Treatment of Prostate Cancer. Urologia Internationalis, 2002, 68, 1-5.	0.6	3
98	Hormone-refractory prostate cancer: what have we learned?. BJU International, 2007, 100, 56-59.	1.3	3
99	Re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. Eur Urol 2014;66:156-163. European Urology, 2014, 66, e13.	0.9	3
100	Testing of a Novel Easy-to-use Mortality Index in a Radical Prostatectomy Cohort. Urology, 2014, 84, 307-313.	0.5	3
101	External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. International Journal of Clinical Oncology, 2020, 25, 145-150.	1.0	3
102	Socioeconomic Status-Related Parameters as Predictors of Competing (Non-Bladder Cancer) Mortality after Radical Cystectomy. Urologia Internationalis, 2020, 104, 62-69.	0.6	3
103	The Clinical Complexity of Penile Cancer: Current Clinical-Epidemiological Data from the Database of the Free State of Saxony/Germany. Urologia Internationalis, 2022, 106, 706-715.	0.6	3
104	Re: Utilization and Outcomes of Minimally Invasive Radical Prostatectomy. European Urology, 2008, 54, 1439-1440.	0.9	2
105	Re: Mortality Results From the Göteborg Randomised Population-Based Prostate-Cancer Screening Trial. European Urology, 2010, 58, 939-940.	0.9	2
106	Radical prostatectomy at young age. BJU International, 2014, 114, 4-5.	1.3	2
107	Reply. Urology, 2014, 84, 312-313.	0.5	2
108	Re: Zhu et al.: The Expression and Evaluation of Androgen Receptor in Human Renal Cell Carcinoma (Urology 2014;83:510.e19-24). Urology, 2014, 84, 734-735.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. <i>Eur Urol</i> 2014;66:666â€“72. <i>European Urology</i> , 2014, 66, e85.	0.9	2
110	Re: Syed Johar Raza, Timothy Wilson, James O. Peabody, et al. Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Eur Urol</i> 2015;68:721â€“8. <i>European Urology</i> , 2015, 68, e109.	0.9	2
111	Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038 . <i>European Urology</i> , 2015, 68, e103.	0.9	2
112	Selection Effects May Explain Smoking-related Outcome Differences After Radical Cystectomy. <i>European Urology Focus</i> , 2018, 4, 395-398.	1.6	2
113	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020, 38, 678-678.	0.8	2
114	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. <i>World Journal of Urology</i> , 2022, 40, 1463-1468.	1.2	2
115	The Management of Localized or Locally Advanced Prostate Cancer. <i>American Journal of Cancer</i> , 2002, 1, 387-396.	0.4	1
116	Re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy. <i>Eur Urol</i> 2014;65:20â€“5. <i>European Urology</i> , 2014, 65, e24.	0.9	1
117	Should the Urologist Treat Castration Resistant Prostate Cancer?. <i>Journal of Urology</i> , 2015, 194, 286-286.	0.2	1
118	Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. <i>Eur Urol</i> 2015;67:212â€“9. <i>European Urology</i> , 2015, 67, e112.	0.9	1
119	Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. <i>Eur Urol</i> 2015;68:805â€“11. <i>European Urology</i> , 2016, 69, e130.	0.9	1
120	OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancerâ€”A phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 115-115.	0.8	1
121	Author reply. , 2000, 88, 2196-2197.		0
122	Predictive Significance of Confirmation Biopsies in Patients on Active Surveillance. <i>European Urology</i> , 2014, 66, 414-415.	0.9	0
123	Prostate-specific Antigen Pox Virus Vaccination for Recurrent Prostate Cancer. <i>European Urology</i> , 2015, 68, 372-373.	0.9	0
124	Simultaneous Targeting of the Akt and Androgen Receptor Pathways. <i>European Urology</i> , 2015, 67, 991-992.	0.9	0
125	Re: Jesse D. Sammon, Firas Abdollah, Anthony Dâ€™Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>Eur Urol</i> 2015;68:756â€“65.. <i>European Urology</i> , 2016, 69, e128.	0.9	0
126	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21â€“30. <i>European Urology</i> , 2016, 70, e9.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Delayed Radiographic Manifestation of Renal Pseudoaneurysms After Blunt Trauma. <i>Urology</i> , 2017, 103, e9-e10.	0.5	0
128	Chronically Infected Urachal Remnant Mimicking Tumor With Peritoneal Carcinomatosis. <i>Urology</i> , 2018, 116, e3-e4.	0.5	0
129	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÄ¶phel, Steffen LÄ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? <i>Eur Urol</i> 2019;75:548Ä¶51. <i>European Urology</i> , 2019, 76, e103-e104.	0.9	0
130	Decreasing NonÄ¶bladder-cancer Mortality After Radical Cystectomy. <i>European Urology Open Science</i> , 2021, 29, 15-18.	0.2	0
131	Local ablative radiotherapy: A means to revert low volume castration-resistant prostate cancer into a hormone-sensitive status?. <i>Journal of Clinical Oncology</i> , 2018, 36, 188-188.	0.8	0